These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
82 related articles for article (PubMed ID: 15645137)
1. Prolactin and heregulin override DNA damage-induced growth arrest and promote phosphatidylinositol-3 kinase-dependent proliferation in breast cancer cells. Chakravarti P; Henry MK; Quelle FW Int J Oncol; 2005 Feb; 26(2):509-14. PubMed ID: 15645137 [TBL] [Abstract][Full Text] [Related]
2. Extracellular matrix enhances heregulin-dependent BRCA1 phosphorylation and suppresses BRCA1 expression through its C terminus. Miralem T; Avraham HK Mol Cell Biol; 2003 Jan; 23(2):579-93. PubMed ID: 12509456 [TBL] [Abstract][Full Text] [Related]
3. Phosphatidylinositol 3-kinase recruitment by p185erbB-2 and erbB-3 is potently induced by neu differentiation factor/heregulin during mitogenesis and is constitutively elevated in growth factor-independent breast carcinoma cells with c-erbB-2 gene amplification. Ram TG; Ethier SP Cell Growth Differ; 1996 May; 7(5):551-61. PubMed ID: 8732665 [TBL] [Abstract][Full Text] [Related]
4. Heregulin beta1-activated phosphatidylinositol 3-kinase enhances aggregation of MCF-7 breast cancer cells independent of extracellular signal-regulated kinase. Tan M; Grijalva R; Yu D Cancer Res; 1999 Apr; 59(7):1620-5. PubMed ID: 10197638 [TBL] [Abstract][Full Text] [Related]
5. Interleukin 6 inhibits proliferation and, in cooperation with an epidermal growth factor receptor autocrine loop, increases migration of T47D breast cancer cells. Badache A; Hynes NE Cancer Res; 2001 Jan; 61(1):383-91. PubMed ID: 11196191 [TBL] [Abstract][Full Text] [Related]
6. Heregulin-beta is especially potent in activating phosphatidylinositol 3-kinase in nontransformed human mammary epithelial cells. Ram TG; Hosick HL; Ethier SP J Cell Physiol; 2000 Jun; 183(3):301-13. PubMed ID: 10797304 [TBL] [Abstract][Full Text] [Related]
7. Prolactin modulates phosphorylation, signaling and trafficking of epidermal growth factor receptor in human T47D breast cancer cells. Huang Y; Li X; Jiang J; Frank SJ Oncogene; 2006 Dec; 25(58):7565-76. PubMed ID: 16785991 [TBL] [Abstract][Full Text] [Related]
8. Src mediates prolactin-dependent proliferation of T47D and MCF7 cells via the activation of focal adhesion kinase/Erk1/2 and phosphatidylinositol 3-kinase pathways. Acosta JJ; Muñoz RM; González L; Subtil-Rodríguez A; Dominguez-Caceres MA; García-Martínez JM; Calcabrini A; Lazaro-Trueba I; Martín-Pérez J Mol Endocrinol; 2003 Nov; 17(11):2268-82. PubMed ID: 12907754 [TBL] [Abstract][Full Text] [Related]
9. Tea polyphenol (-)-epigallocatechin 3-gallate suppresses heregulin-beta1-induced fatty acid synthase expression in human breast cancer cells by inhibiting phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase cascade signaling. Pan MH; Lin CC; Lin JK; Chen WJ J Agric Food Chem; 2007 Jun; 55(13):5030-7. PubMed ID: 17539658 [TBL] [Abstract][Full Text] [Related]
10. ErbB2-overexpressing human mammary carcinoma cells display an increased requirement for the phosphatidylinositol 3-kinase signaling pathway in anchorage-independent growth. Hermanto U; Zong CS; Wang LH Oncogene; 2001 Nov; 20(51):7551-62. PubMed ID: 11709727 [TBL] [Abstract][Full Text] [Related]
11. [The effect of HER2/neu overexpression on p53 gene expression, cell proliferation and sensitivity to gamma-irradiation via the PI3K/Akt pathway in breast cancer cell MCF7]. Zheng L; Ren JQ; Chen Q; Zhang HP; Zhu HG Zhonghua Zhong Liu Za Zhi; 2004 Oct; 26(10):594-7. PubMed ID: 15634518 [TBL] [Abstract][Full Text] [Related]
12. Up-regulation of vascular endothelial growth factor in breast cancer cells by the heregulin-beta1-activated p38 signaling pathway enhances endothelial cell migration. Xiong S; Grijalva R; Zhang L; Nguyen NT; Pisters PW; Pollock RE; Yu D Cancer Res; 2001 Feb; 61(4):1727-32. PubMed ID: 11245489 [TBL] [Abstract][Full Text] [Related]
13. Differential signaling by an anti-p185(HER2) antibody and heregulin. Le XF; Vadlamudi R; McWatters A; Bae DS; Mills GB; Kumar R; Bast RC Cancer Res; 2000 Jul; 60(13):3522-31. PubMed ID: 10910064 [TBL] [Abstract][Full Text] [Related]
14. Heregulin-triggered Her-2/neu signaling enhances nuclear accumulation of p21WAF1/CIP1 and protects breast cancer cells from cisplatin-induced genotoxic damage. Menendez JA; Mehmi I; Lupu R Int J Oncol; 2005 Mar; 26(3):649-59. PubMed ID: 15703820 [TBL] [Abstract][Full Text] [Related]
15. Signal transduction pathways induced by heregulin in MDA-MB-453 breast cancer cells. Sepp-Lorenzino L; Eberhard I; Ma Z; Cho C; Serve H; Liu F; Rosen N; Lupu R Oncogene; 1996 Apr; 12(8):1679-87. PubMed ID: 8622888 [TBL] [Abstract][Full Text] [Related]
16. Essential role for Rac in heregulin beta1 mitogenic signaling: a mechanism that involves epidermal growth factor receptor and is independent of ErbB4. Yang C; Liu Y; Lemmon MA; Kazanietz MG Mol Cell Biol; 2006 Feb; 26(3):831-42. PubMed ID: 16428439 [TBL] [Abstract][Full Text] [Related]
17. FOXO transcription factors enforce cell cycle checkpoints and promote survival of hematopoietic cells after DNA damage. Lei H; Quelle FW Mol Cancer Res; 2009 Aug; 7(8):1294-303. PubMed ID: 19671690 [TBL] [Abstract][Full Text] [Related]
18. Cytokine activation of phosphoinositide 3-kinase sensitizes hematopoietic cells to cisplatin-induced death. Nimbalkar D; Henry MK; Quelle FW Cancer Res; 2003 Mar; 63(5):1034-9. PubMed ID: 12615719 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of either phosphatidylinositol 3-kinase/Akt or the mitogen/extracellular-regulated kinase, MEK/ERK, signaling pathways suppress growth of breast cancer cell lines, but MEK/ERK signaling is critical for cell survival. Ripple MO; Kalmadi S; Eastman A Breast Cancer Res Treat; 2005 Sep; 93(2):177-88. PubMed ID: 16187238 [TBL] [Abstract][Full Text] [Related]
20. Heregulin-beta1 promotes metastasis of breast cancer cell line SKBR3 through upregulation of Snail and induction of epithelial-mesenchymal transition. Cheng L; Zha Z; Lang B; Liu J; Yao X Cancer Lett; 2009 Jul; 280(1):50-60. PubMed ID: 19269083 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]